P093 Changes in the flowcytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

“…29 Preliminary data indicate that immunophenotypic MDS-related abnormalities in bone marrow cells are no longer detectable or decrease in number in responding patients compared with pretreatment analysis. 30 In conclusion, our data underscore observations that Epo/ G-CSF is an effective first-line treatment regimen in a subgroup of patients with low-and intermediate-I-risk MDS with a low serum Epo level and low transfusion need. Notably, aberrant immunophenotype of myeloid blasts acted as a significant and cost-effective biomarker for response to Epo/G-CSF treatment in combination with Epo levels at validated thresholds.…”

Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias

“…A thorough understanding of the phenotypic changes that accompany normal development of MyPC, monocytes, maturing myeloid cells, and erythroid cells (21–27) has led to the observation that MDS marrows differ in their patterns of development to a variable degree, often associated with severity of disease (5, 20, 28–30). The aberrant FCM patterns in MDS reflect disrupted coordination of gene regulation with an accumulation of these abnormalities indicating progression of MDS.…”

“…The FCSS has already been shown to subdivide the IPSS (5). A constant across all techniques for prognosis in MDS is that the accumulation of abnormalities is connected to worse outcomes (5, 20, 28–30). The FCSS ability to detect a range of surface marker abnormalities could be a key metric to further evaluate prognosis.…”